focalinterest.com

AI Summary of Peer-Reviewed Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Publishing process signals: STRONG — reflects the venue and review process. — venue and review process.

Olutasidenib showed disease control in conventional chondrosarcoma

—

in
A black and white photograph showing a medical professional in a white coat examining a young female patient's eye or face area with a handheld diagnostic instrument, representing a clinical consultation.
Research area:OncologySarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

What the study found

Olutasidenib, an IDH1 inhibitor, was well tolerated in patients with recurrent or relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma. The study reported disease control in conventional chondrosarcoma, a subtype of this cancer.

Why the authors say this matters

The authors note that chondrosarcomas have limited treatment options and that IDH1/2 mutations are common in these tumors. The study suggests olutasidenib may have relevance for patients with conventional chondrosarcoma because the findings indicate disease control in that group.

What the researchers tested

This was a phase 1b/2 trial in patients with locally advanced or metastatic IDH1-mutated chondrosarcoma (Clinicaltrials.gov identifier NCT03684811). Patients received olutasidenib 150 mg twice daily, and the main outcome was objective response rate by tumor evaluation; safety, progression-free survival, and overall survival were also assessed.

What worked and what didn't

Twenty-three patients were enrolled, including 16 with conventional chondrosarcoma. In 21 response-evaluable patients, 11 had stable disease, 8 had progressive disease, and 2 were not evaluable; among conventional chondrosarcoma patients, 10 had stable disease and 6 had progressive disease. Median progression-free survival was 2.0 months overall and 3.5 months in conventional chondrosarcoma, and no dose-limiting toxicities were reported.

What to keep in mind

The abstract states that the study was open-label and included a low number of patients because conventional chondrosarcoma is rare. It also provides no additional limitations beyond these points.

Key points

  • Olutasidenib was evaluated in recurrent or relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma.
  • The study reported no dose-limiting toxicities.
  • In response-evaluable patients, 52% had stable disease and 38% had progressive disease.
  • Among conventional chondrosarcoma patients, 63% had stable disease and 38% had progressive disease.
  • Median progression-free survival was 2.0 months overall and 3.5 months in conventional chondrosarcoma.

Disclosure

Research title:
Olutasidenib showed disease control in conventional chondrosarcoma
Authors:
Robin L. Jones, Roman Groisberg, Jean-Yves Blay, H. Colman, M. De La Fuente, Patricia Roxburgh, Mwe Mwe Chao, Hua Tian, Florence Duffaud, Rastislav Bahleda, Brian A. Van Tine
Institutions:
Aix-Marseille Université, Centre Léon Bérard, Huntsman Cancer Institute, Institut Gustave Roussy, Rigel (United States), Rigel (United States), Royal Marsden Hospital, Rutgers Cancer Institute, Rutgers, The State University of New Jersey, Sylvester Comprehensive Cancer Center, University of Glasgow, University of Miami, University of Utah, Washington University in St. Louis
Publication date:
2026-01-29
DOI:
10.1038/s41467-026-68716-6
OpenAlex record:
View
AI provenance: This post was generated by gpt-5.4-mini (OpenAI). The original authors did not write or review this post.